• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

整合素结合肽ATN-161作为治疗新型冠状病毒肺炎的新疗法

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.

作者信息

Beddingfield Brandon J, Iwanaga Naoki, Chapagain Prem P, Zheng Wenshu, Roy Chad J, Hu Tony Y, Kolls Jay K, Bix Gregory J

机构信息

Division of Microbiology, Tulane National Primate Research Center, Covington, Louisiana, USA.

Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.

出版信息

JACC Basic Transl Sci. 2021 Jan;6(1):1-8. doi: 10.1016/j.jacbts.2020.10.003. Epub 2020 Oct 16.

DOI:10.1016/j.jacbts.2020.10.003
PMID:33102950
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7566794/
Abstract

Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin-based mechanism and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/- ACE2) and the interaction between α5β1 integrin and ACE2 using a novel molecule (ATN-161) represents a promising approach to treat coronavirus disease-19.

摘要

为应对当前的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行，许多设计和筛选治疗方法的努力都集中在通过破坏血管紧张素转换酶2（ACE2）与SARS-CoV-2刺突蛋白的结合来抑制病毒进入宿主细胞。这项研究聚焦于通过一种基于α5β1整合素的假定机制来抑制SARS-CoV-2进入的潜力，并表明使用一种新型分子（ATN-161）抑制刺突蛋白与α5β1整合素（±ACE2）的相互作用以及α5β1整合素与ACE2之间的相互作用，是一种治疗冠状病毒病19的有前景的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/de61f6fb4b82/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/a41f08e751b4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/bb9aead1fcbe/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/c5e3db413cfc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/de61f6fb4b82/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/a41f08e751b4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/bb9aead1fcbe/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/c5e3db413cfc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac70/7838047/de61f6fb4b82/gr3.jpg

相似文献

1
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.整合素结合肽ATN-161作为治疗新型冠状病毒肺炎的新疗法
JACC Basic Transl Sci. 2021 Jan;6(1):1-8. doi: 10.1016/j.jacbts.2020.10.003. Epub 2020 Oct 16.
2
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.整合素结合肽ATN-161作为治疗新型冠状病毒2019感染的新疗法
bioRxiv. 2020 Jul 24:2020.06.15.153387. doi: 10.1101/2020.06.15.153387.
3
Preventive treatment of coronavirus disease-2019 virus using coronavirus disease-2019-receptor-binding domain 1C aptamer by suppress the expression of angiotensin-converting enzyme 2 receptor.使用新型冠状病毒病-2019受体结合域1C适体通过抑制血管紧张素转换酶2受体的表达来预防新型冠状病毒病-2019病毒
J Adv Pharm Technol Res. 2023 Jul-Sep;14(3):185-190. doi: 10.4103/JAPTR.JAPTR_117_23. Epub 2023 Jul 28.
4
Penta-peptide ATN-161 based neutralization mechanism of SARS-CoV-2 spike protein.基于五肽ATN-161的新冠病毒刺突蛋白中和机制
Biochem Biophys Rep. 2021 Dec;28:101170. doi: 10.1016/j.bbrep.2021.101170. Epub 2021 Nov 10.
5
In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice.在 k18-hACE2 转基因小鼠中，ATN-161 对 SARS-CoV-2 感染的体内保护作用。
Life Sci. 2021 Nov 1;284:119881. doi: 10.1016/j.lfs.2021.119881. Epub 2021 Aug 10.
6
Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的抑制剂筛选及其阻断病毒进入机制的能力：一项病毒信息学研究。
Saudi J Biol Sci. 2021 Jun;28(6):3262-3269. doi: 10.1016/j.sjbs.2021.02.066. Epub 2021 Feb 26.
7
Integrin αβ contributes to cell fusion and inflammation mediated by SARS-CoV-2 spike via RGD-independent interaction.整合素 αβ 通过非 RGD 依赖性相互作用促进 SARS-CoV-2 刺突介导的细胞融合和炎症反应。
Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2311913120. doi: 10.1073/pnas.2311913120. Epub 2023 Dec 7.
8
Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.用于阻断新冠病毒刺突蛋白受体结合域的潜在嵌合肽。
F1000Res. 2020 Jun 9;9:576. doi: 10.12688/f1000research.24074.1. eCollection 2020.
9
1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection.1,2,3,4,6-五没食子酰葡萄糖，一种RBD-ACE2结合抑制剂，用于预防新型冠状病毒感染。
Front Pharmacol. 2021 Mar 4;12:634176. doi: 10.3389/fphar.2021.634176. eCollection 2021.
10
Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.基于 SARS-CoV-2 刺突蛋白/血管紧张素转化酶 2 复合物的丙氨酸扫描计算和结构分析。
ACS Nano. 2020 Sep 22;14(9):11821-11830. doi: 10.1021/acsnano.0c04674. Epub 2020 Aug 26.

引用本文的文献

1
The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management.新型冠状病毒肺炎血栓形成：区分病理、机制、表型特征及管理
J Thromb Thrombolysis. 2025 Jan;58(1):15-49. doi: 10.1007/s11239-024-03028-4. Epub 2024 Aug 23.
2
Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.鉴定与 SARS-CoV-2 刺突蛋白受体结合域相互作用的新型宿主细胞因子。
J Biol Chem. 2024 Jun;300(6):107390. doi: 10.1016/j.jbc.2024.107390. Epub 2024 May 21.
3
SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors.

本文引用的文献

1
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.从头设计皮摩尔级 SARS-CoV-2 小蛋白抑制剂。
Science. 2020 Oct 23;370(6515):426-431. doi: 10.1126/science.abd9909. Epub 2020 Sep 9.
2
Environmental and Aerosolized Severe Acute Respiratory Syndrome Coronavirus 2 Among Hospitalized Coronavirus Disease 2019 Patients.环境和空气传播的严重急性呼吸综合征冠状病毒 2 在住院的 2019 年冠状病毒病患者中。
J Infect Dis. 2020 Nov 9;222(11):1798-1806. doi: 10.1093/infdis/jiaa575.
3
COVID-19 and Kidney Disease: Update on Epidemiology, Clinical Manifestations, Pathophysiology and Management.
考虑宿主因素的SARS-CoV-2在各器官中的细胞嗜性机制。
Heliyon. 2024 Feb 20;10(4):e26577. doi: 10.1016/j.heliyon.2024.e26577. eCollection 2024 Feb 29.
4
Development of SARS-CoV-2 entry antivirals.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入抑制剂的研发。
Cell Insight. 2024 Jan 30;3(1):100144. doi: 10.1016/j.cellin.2023.100144. eCollection 2024 Feb.
5
Integrin αβ contributes to cell fusion and inflammation mediated by SARS-CoV-2 spike via RGD-independent interaction.整合素 αβ 通过非 RGD 依赖性相互作用促进 SARS-CoV-2 刺突介导的细胞融合和炎症反应。
Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2311913120. doi: 10.1073/pnas.2311913120. Epub 2023 Dec 7.
6
Cryo-electron microscopy in the fight against COVID-19-mechanism of virus entry.冷冻电子显微镜技术在抗击新冠病毒中的应用——病毒进入机制
Front Mol Biosci. 2023 Oct 6;10:1252529. doi: 10.3389/fmolb.2023.1252529. eCollection 2023.
7
Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities.整合素信号在癌症中的作用：双向机制与治疗机遇。
Cell Commun Signal. 2023 Sep 28;21(1):266. doi: 10.1186/s12964-023-01264-4.
8
Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams.抗转移性肿瘤的小分子：切实的前景与破灭的梦想。
Cancers (Basel). 2023 Aug 18;15(16):4173. doi: 10.3390/cancers15164173.
9
Identification of host receptors for viral entry and beyond: a perspective from the spike of SARS-CoV-2.病毒进入及其他过程中宿主受体的鉴定：来自严重急性呼吸综合征冠状病毒2刺突蛋白的视角
Front Microbiol. 2023 Jul 25;14:1188249. doi: 10.3389/fmicb.2023.1188249. eCollection 2023.
10
Single-cell analysis of adult human heart across healthy and cardiovascular disease patients reveals the cellular landscape underlying SARS-CoV-2 invasion of myocardial tissue through ACE2.单细胞分析健康和心血管疾病患者的成人心脏，揭示了通过 ACE2 入侵心肌组织的 SARS-CoV-2 的细胞景观。
J Transl Med. 2023 May 31;21(1):358. doi: 10.1186/s12967-023-04224-1.
2019冠状病毒病与肾脏疾病：流行病学、临床表现、病理生理学及管理的最新进展
J Coll Physicians Surg Pak. 2020 Jun;30(6):19-25. doi: 10.29271/jcpsp.2020.Supp1.S19.
4
New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection.新冠病毒的新策略：RGD基序在严重急性呼吸综合征冠状病毒2中的进化作用及病毒感染的潜在抑制剂
Front Pharmacol. 2020 Jun 12;11:912. doi: 10.3389/fphar.2020.00912. eCollection 2020.
5
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?利妥昔单抗治疗多发性硬化症患者合并 COVID-19：整合素阻断是否具有保护作用？
Mult Scler Relat Disord. 2020 Sep;44:102250. doi: 10.1016/j.msard.2020.102250. Epub 2020 Jun 3.
6
Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions.通过氢键和疏水相互作用网络增强 SARS-CoV-2 的受体结合。
Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):13967-13974. doi: 10.1073/pnas.2008209117. Epub 2020 Jun 5.
7
A human monoclonal antibody blocking SARS-CoV-2 infection.一种人源单克隆抗体阻断 SARS-CoV-2 感染。
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
8
The proximal origin of SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的近端起源。
Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9.
9
A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2.整合素在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体靶向中的潜在抑制作用。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.046. Epub 2020 Apr 10.
10
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.